EvolveImmune Therapeutics Highlights Progress for Lead Asset EVOLVE104 and EVOLVE T Cell Engager Platform in Multiple Presentations at 2026 AACR Annual Meeting

Phase 1 Clinical Trial of EVOLVE104 Continues to Advance According to PlanOral Minisymposium Presentation Demonstrates That EVOLVE T Cell ...
EurekAlert!

Proximity between LAG-3 and the T cell receptor guides suppression of T cell activation and autoimmunity (IMAGE)

LAG-3 exerts its inhibitory function by undergoing phase separation with the CD3ε subunit of the TCR/CD3 complex; Enhancing the cis-proximity between LAG-3 and TCR through a LAG-3/TCR bispecific ...
MarketersMEDIA Newsroom

KACTUS Publishes Framework for 2+1 and Trispecific TCE Scaffold Design

KACTUS has published a technical framework for engineering 2+1 and trispecific T-cell engager therapeutics, addressing structural scaffold challenges for drug discovery teams advancing beyond ...
The American Journal of Managed Care

Study Identifies Key Predictors of Successful CD3+ Cell Apheresis for CAR T Manufacturing in DLBCL

Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...
Pharmabiz

ModeX Therapeutics initiates clinical trial of tetraspecific antibody for treatment of B-cell lymphomas

ModeX Therapeutics initiates clinical trial of tetraspecific antibody for treatment of B-cell lymphomas: Weston, Massachusetts Friday, April 24, 2026, 16:00 Hrs [IST] ModeX Therap ...